Advertisement
< Vol. 18 Issue 3 | May-Jun 2017 | pp. 177 - 272, e27 - e38

Evaluating safety, efficacy, and cost-effectiveness of PICC securement by subcutaneously anchored stabilization device

Abstract

Purpose

In recent years, a large variety of medical devices has become available. Every device must be efficient, safe and cost effective, but it is not enough to use it properly without considering the environment in which it will be employed. We applied this kind of analysis to subcutaneously anchored sutureless devices (SAS).

 Methods

This is a one-center prospective observational study on safety, effectiveness and cost effectiveness of an SAS device (SecurAcath, Interrad) for securement of peripherally inserted central catheter (PICC) in 30 adult cancer patients with treatment expected to be >60 days.

 Results

During 4963 catheter days and after 709 dressing changes (documented by 373 pictures), the use of SAS was associated with no episode of PICC dislodgement and a lower incidence of complications if compared to traditional securement devices. Insertion, management and removal of SAS were not associated with an increased pain perception by the patients. Cost effectiveness was particularly evident for long dwelling PICCs.

 Conclusions

Our study suggests that SAS is a highly effective and cost-effective method for securement of medium- to long-term PICCs with expected duration longer than 30 days. The introduction of SAS had a positive impact on our healthcare organization.

J Vasc Access 2017; 18(3): 238 - 242

Article Type: ORIGINAL RESEARCH ARTICLE

DOI:10.5301/jva.5000655

Authors

Pietro Antonio Zerla, Antonio Canelli, Lidia Cerne, Giuseppe Caravella, Alessandra Gilardini, Giuseppe De Luca, Ana Maria Aricisteanu, Raffaele Venezia

Article History

  • • Accepted on 23/11/2016
  • • Available online on 15/02/2017
  • • Published in print on 15/05/2017

Disclosures

Financial support: No grants or funding have been received for this study.
Conflict of interest: None of the authors has financial interest related to this study to disclose.

This article is available as full text PDF.

  • If you are a Subscriber, please log in now.

  • Article price: Eur 36,00
  • You will be granted access to the article for 72 hours and you will be able to download any format (PDF or ePUB). The article will be available in your login area under "My PayPerView". You will need to register a new account (unless you already own an account with this journal), and you will be guided through our online shop. Online purchases are paid by Credit Card through PayPal.
  • If you are not a Subscriber you may:
  • Subscribe to this journal
  • Unlimited access to all our archives, 24 hour a day, every day of the week.

Authors

Affiliations

  •  ASST Melegnano e della Martesana, Vizzolo Predabissi, Milan - Italy
  •  Hospital Pharmacy, ASST Melegnano e della Martesana, Milan - Italy
  •  SITRA, ASST Melegnano e della Martesana, Milan - Italy
  •  Oncology, ASST Melegnano e della Martesana, Milan - Italy

Article usage statistics

The blue line displays unique views in the time frame indicated.
The yellow line displays unique downloads.
Views and downloads are counted only once per session.

No supplementary material is available for this article.